CM
SRPT icon

Crestline Management’s Sarepta Therapeutics SRPT Stock Holding History

Crestline Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-33,893
Closed -$4.12M – 558
2024
Q4 		$4.12M Buy
+33,893
New +$4.15M 0.14% 168
2018
Q3 		– Sell
-14,160
Closed -$1.87M – 227
2018
Q2 		$1.87M Buy
+14,160
New +$1.34M 0.2% 149
2017
Q3 		– Sell
-61,410
Closed -$2.07M – 168
2017
Q2 		$2.07M Buy
61,410
+28,810
+88% +$938K 0.28% 37
2017
Q1 		$965K Buy
+32,600
New +$1.01M 0.18% 56

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Crestline Management's SRPT Position: Q1 2025 in Review

Crestline Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 33,893 shares — an estimated $4.12M sold.

Crestline Management first reported a position in SRPT in Q1 2017 and held it in 4 quarters. The position peaked at $4.12M in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Crestline Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 33,893 Sarepta Therapeutics shares in Q1 2025, an estimated $4.12M.
  • Crestline Management first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 4 quarters.
  • Crestline Management's Sarepta Therapeutics position peaked at $4.12M in Q4 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.